Kailera Therapeutics, Inc. Common Stock (KLRA) is a publicly traded the market company. As of August 8, 2026, KLRA trades at $18.58 with a market cap of $2.35B and a P/E ratio of 0.00. KLRA moved -1.99% today. Year to date, KLRA is +0.00%; over the trailing twelve months it is flat. Its 52-week range spans $16.39 to $28.23. Analyst consensus is strong buy with an average price target of $45.00. Rallies surfaces KLRA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Kailera Therapeutics Shares Slump 10% on 62% Nausea, 38% Vomiting Rate: Shares of Kailera Therapeutics fell 10% after Phase 3 data revealed 62% of participants experienced moderate-to-severe nausea and 38% reported vomiting. The trial still showed an average 11% body weight reduction at 24 weeks but safety concerns now cast doubt on approval timeline.
| Metric | Value |
|---|---|
| Price | $18.58 |
| Market Cap | $2.35B |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $28.23 |
| 52-Week Low | $16.39 |
| Volume | 93.32K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
5 analysts cover KLRA: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $45.00.